demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 prophylaxis (excluding children)
neutralizing antibody
bamlanivimab monotherapy BLAZE-2 US ...
casirivimab/imdevimab (Ronapreve) Cov-2069 ...
cilgavimab and tixagevimab (Evusheld) PROVENT

5 studies excluded by filtering options 1

6708 Webb, 2021 0130selection pending
6920 Rainwater-Lovett, 2021 0130selection pending
6921 Bariola, 2021 1130not a RCTrisk of bias not avaialble
9866 Jurdi, 2022 1110not a RCTrisk of bias not avaialble
10191 Chen, 2022 0100selection pending